Vital4Cholest™
180 tablets

Vital4Cholest™ is a powerful combination of four natural ingredients, policosanol, phytosterols, citrus polymethoxylated flavones and palm tocotrienols to help maintain a healthy cardiovascular system.*

Diets low in saturated fat and cholesterol that include two servings of foods that provide a daily total of at least .65 g of phytosterol esters or .4 g of free phytosterols per serving in two meals may reduce the risk of heart disease. A daily serving of Vital4Cholest™ supplies 800 mg of free phytosterols.

Supplement Facts

Serving Size 2 tablets
Servings Per Container 30

Amount Per Serving
Phytosterols (std to 90% total sterols) (as free sterols)........................800 mg
Sytrinol® .......................................................................300 mg
(Proprietary blend of citrus polymethoxylated flavones and palm tocotrienols)
Biocosanol® (std to 90% Policosanol - sugar cane derived).........................20 mg
Other ingredients: microcrystalline cellulose, calcium silicate, croscarmellose sodium, 
stearic acid, magnesium stearate, hydroxypropyl methylcellulose, triacetin food grade, 
talc, chlorophyll, titanium dioxide.

This product contains NO milk, egg, fish, peanuts, crustacean shellfish, soybeans, tree nuts, wheat, yeast, or gluten.
Contains NO sugar, and no artificial sweeteners, flavors, colors, or preservatives.
Although manufacturing equipment is thoroughly cleansed after all production runs, this product is manufactured in a facility that utilizes milk, egg, fish, peanuts, crustacean shellfish, soybeans, tree nuts, wheat, yeast, and gluten.

Directions: Take one (1) tablet twice daily with food, or as directed by your physician.

References

Kurowska EM, Manthey JA. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem. 2004 May 19;52(10):2879-86.

Maron DJ. Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep. 2004 Jan;6(1):73-8.

Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1999 Apr;65(4):439-47.

Prat H, Roman O, Piro E. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil. 1999 Mar;127(3):286-94. Spanish.

Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React. 1998;20(4):119-24.

Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res. 1997 Oct;36(4):293-7.

Torres O, Agramante AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995 Mar;18(3):393-7.

Hernandez F, Illnait J, Mas R, et al. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. Current Therap Res. 1992; 52:568-575.

Baliarsingh S, Beg ZH, Ahmad J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis. 2005 Oct;182(2):367-74. Epub 2005 Apr 20.

Quereshi AA, Bradlow BA, Manganello J, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids. 1995 Dec;30(12):1171-7.

Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids. 1995 Dec;30(12):1179-83.

Qureshi AA, Qureshi N, Wright JJ, et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr. 1991 Apr;53(4 Suppl):1021S-1026S.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.